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CLINICAL AND SYSTEMATIC REVIEWS
Fistulizing Crohn’s Disease
Michael Scharl, MD1, Gerhard Rogler, MD, PhD1 and Luc Biedermann, MD1
Fistulas still represent one of the most important complications in patients with Crohn’s disease (CD). At least one third of CD
patients suffer from fistulas during their disease course and amongst them longstanding remission of complex fistulas occurs
only in about one third. So far, fistula pathogenesis is only partially understood. From a histopathological view, a fistula is a tube
covered by flat epithelial cells. Current research suggests that the driving force for fistula development is epithelial-to-
mesenchymal transition (EMT). Around the fistula, high levels of tumor necrosis factor (TNF), IL-13, and TGFβ can be detected and
recent studies indicated an involvement of the intestinal microbiota. Fistula diagnosis requires clinical and surgical assessment,
radiologic investigations, e.g., magnet resonance imaging and endoscopy. Routine medical treatment of fistulas includes
antibiotics, immunosuppressives, and anti-TNF antibodies. There is no well-established role for calcineurin inhibitors in fistula
treatment, corticosteroids appear to be even contra-productive. A promising novel approach might be the application of adipose
tissue-derived or bone marrow-derived mesenchymal stem cells that have been studied recently. Due to insufficient efficacy of
medical treatment and recurrence of fistulas, surgical interventions are frequently necessary. Further research is needed to better
understand fistula pathogenesis aiming to develop novel treatment option for our patients.
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INTRODUCTION
The first description of perianal fistulas as a typical complica-
tion of terminal ileitis was published in 1938.1 Population-
based studies indicate that one third of Crohn’s disease (CD)
patients will develop fistulas at least once during the disease
course. Hereby, perianal fistulas are most common.2 At time of
CD diagnosis, two third of patients present with inflammatory
disease and only up to one-third of the patients reveal
stricturing or penetrating complications in the gastrointestinal
tract.3,4 Nevertheless, during a longstanding and relapsing
disease course, frequently a shift from the inflammatory
disease phenotype towards a stricturing and/or penetrating
phenotype is observed. Newer epidemiological data suggests
that the risk of developing a stricturing or penetrating
phenotype over time has somewhat decreased within the last
years, specifically in those patients with elderly onset of CD.5
Population-based studies indicate that longer disease dura-
tion increases the cumulative incidence of perianal fistulas.
The cumulative frequency in year 1 is 12%, after 5 years it is
15%, after 10 years 21, and after 20 years 26%.2 Further, the
incidence of perianal fistulas depends on disease location.
Perianal fistulas are most common in patients suffering from
colonic CD with rectal involvement (92% of patients) but are
rare in patients with isolated ileal disease (12% of patients).6
About 10% of CD patients present with perianal fistulas as first
disease manifestation either together with luminal inflamma-
tion or not. In some patients, perianal fistulas may even occur
years before the onset of luminal inflammation.2,6 However, in
the vast majority of patients (95%) perianal disease activity is
paralleled by luminal disease activity and only in 5% of the
patients perianal disease activity is detectable in patients
without luminal inflammation.7 Besides fistulas, a significant
number of CD patients develops intestinal fibrosis and
strictures. Together, fistulas and stenosis affect ~ 70% of CD
patients during life time and presence of stenosis frequently
results in the onset of intestinal obstruction.8 Bowel resections
reduce the risk for developing fistulas.9
CLASSIFICATION AND PREDICTIVE FACTORS
Fistulas can be discriminated into simple and complex fistulas.
A simple fistula is a low fistula with only a single external
opening and is not associated with abscess formation,
rectovaginal fistula, or an anorectal stricture. However, simple
fistulas might be associated with active and severe rectal
disease.10 A low fistula is characterized by a tract that
penetrates the lower one-third of the external anal sphincter.
After a follow-up period of 10 years about one third of patients
suffer from persistent perianal fistulas according to a study
from 1980. The remaining two third of patients either under-
went surgery or experienced spontaneous healing.11 A more
recent study revealed that recurrence of clinically healed
fistulas is 44% within 18 months.12 The chance of fistula
healing depends on fistula location. Superficial and low fistulas
have a higher healing rate when treated by fistulotomy,
especially in the absence of proctitis.13 In contrast, in patients
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with high fistulas or presence of proctitis a considerably lower
healing rate and risk for postoperative incontinence has been
reported.14,15 In line with this, absence of proctitis indepen-
dently predicts both, enhanced healing and reduced recur-
rence rates.12 In contrast, in patients with perianal CD and
rectal involvement proctectomy is more frequent.16
In a single center study involving 232 patients with perianal
CD longstanding remission for complex fistulas was seen in
only 37% of patients after a 10-year follow-up compared with
almost 67% for simple fistulas.17 A recent systematic review
concluded that a combination of medical and surgical
treatment approaches is superior to either single treatment
alone. The importance of a multidisciplinary patient care is
highlighted by superior rates of complete remission (52%) in
the combination vs. single therapy (43%) group.18 In female
patients of child-bearing age with established CD the
cumulative probability of developing perianal fistulas following
delivery is 8% after 1 year, 12% after 2 years, and 21% after 5
years. This probability is lower as in the general CD
population. However, perianal disease is also associated with
fewer pregnancies.19
An important and worrysome aspect of fistulizing CD is the
occurrence of malignant transformation of perianal fistulas.
Although this event is rare, it nevertheless is of crucial
importance for the affected patients. In a systematic review
from 2010, 61 cases of carcinomas arising in perineal fistulas
in CD patients have been described, the majority in female
patients (61%). Interestingly, females were significantly
younger at time of cancer diagnosis, had shorter duration of
CD, and suffered from fistula formation for a shorter duration
prior to cancer transformation as compared to males. The
most frequent histological subtype was adenocarcinoma
(59%), followed by squamous cell carcinoma (31%). Fistulas
were most frequently from rectal origin.20 In a Dutch multi-
center study containing more than over 6,000 CD patients,
only four cases of fistula-associated adenocarcinoma were
detected. This observation confirms that carcinomas arising
from fistula tracts are a rare event in CD patients.21
PATHOGENESIS
Fistulas are thought to arise as consequence of an acute
inflammatory process paralleled by infection and
suppuration.22 From a morphological point of view, a fistula
represents a tract between two surfaces that is lined by
epithelial cells and filled with cell debris, erythrocytes, and
inflammatory cells.23 A chronic inflammatory infiltrate and
fibrosis are common findings surrounding the fistula tract. In
~ 30% of intestinal or perianal CD fistulas the tracts are
covered by flattened intestinal epithelial cells or squamous
epithelial cells. In contrast, ~ 70% of CD fistula tracts are
covered by a thin layer of myofibroblast-like cells, so-called
“transitional cells”, forming a newbasalmembrane. CD fistulas
show a central infiltration by CD45R0+ T-cells, an underlying
band of CD68+ macrophages and a dense CD20+ B-cell
infiltrate in the outer wall.23 In perianal fistulas accumulation of
CD4+ CD161+ T-cells with a Th17, Th17/Th1, and Th1
phenotype has been described.24 Kirkegaard et al. found a
strong expression of matrix remodeling enzymes, namely
matrix metallo-proteinase (MMP)-3 and MMP-9 around CD
fistulas while expression of tissue inhibitors of MMP (TIMP)-1,
TIMP-2 and TIMP-3 was lower as compared to normal colon
tissue. This indicates an altered balance between MMPs and
TIMPs in and around CD fistulas resulting in aberrant extra-
cellular matrix degradation.25
Current hypothesis suggests that epithelial-to-
mesenchymal transition (EMT) is the driving force behind the
development of fistulas in CD patients. Though EMT is
involved in important mechanisms such as embryogenesis,
organ development, wound healing, and tissue remodeling,
EMT plays also a major role for pathological processes such
as tissue fibrosis and cancer progression.26,27 During EMT
epithelial cells lose epithelial-specific characteristics, such as
apico-basal polarity and epithelial-specific cell contacts, but
reacquire a mesenchymal cell shape and exhibit enhanced
motility and cell spreading.26 On a molecular level, EMT is
characterized by down-regulation of epithelial cell specific
proteins, such as E-cadherin or claudin-4, and upregulation of
mesenchymal proteins, such as alpha smooth muscle actin
and vimentin.26 EMT-associated transcription factors, such as
SNAIL, SLUG, and ETS-1, as well as markers for cell
proliferation and migration, such as β6-integrin are expressed
in or around CD fistula tracts.28,29
Presence of fistulas correlates with elevated serum levels of
the proinflammatory cytokines tumor necrosis factor (TNF)
and IL-6. In rectal mucosa expression of IL-1β and IL-6 is
higher in patients with perianal CD than in those with small
bowel CD and in healthy controls.30 Upregulation of TNF and
IL-12 in resected intestinal tissue from patients with CD was
correlated with fistula development. Analysis of cytokine
expression patterns in the epithelial lining of CD fistula tracts
revealed that TNF and TNF receptor I are highly expressed by
epithelial cells as well as immune cells surrounding the fistula
tract and also by epithelial cells of the adjacent crypts.29
Further, IL-13, IL-13α1, and transforming growth factor
(TGF)-β, the strongest inducer of EMT, are detectable in
fistula lining cells.28,31
Data from the IBDchip European Project including 1528
Caucasian patients suggest that genetic factors differently
modulate the risk for perianal disease and internal fistulas.32
On the one hand, variations within the genes encoding
PRDM1, NOD2, IL-23 receptor, ATG16L1 are associated with
onset of internal fistulas and internal penetrating disease. On
the other hand, significant associations between the NOD2
variant rs72796353 as well as variations within the gene loci
encoding TNFSF15, OCTN, IBD5 locus on 5q31, IRGM,
DLG5 (in pediatric CD) and NCF4 and the onset of perianal
fistulas have been found.33–38
Recent data also suggest a role for the intestinal microbiota
in fistula pathogenesis. By analyzingmicrobiota from the distal
part of surgically removed fistula tracts, bowel- and/or skin-
derived bacteria, but no mycobacteria were identified.
Peptidoglycans were detected in ~ 90% of those patient
samples suggesting that peptidoglycan might contribute to
the ongoing inflammation and therefore development of
perianal fistulas.39 This assumption would be supported by
the fact that peptidoglycan is also able to induce the
expression of EMT-associated molecules.40 In a study that
assessed the microbiota within fistula tracts of CD patients a
predominance of Gram-positive bacteria (staphylococci and
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streptococci) over Gram-negative bacteria was found41
(Figure 1).
DIAGNOSIS
The accurate diagnosis is the prerequisite for and the first step
in the optimal management of patients with perianal fistulizing
CD. To obtain the correct diagnosis of fistulizing disease a
number of different techniques have been described, such
as examination under anesthesia (EUA) and imaging by
endoscopic ultasonography (EUS) or magnet resonance
imaging (MRI).
The current standard of care guidelines on the diagnosis
and treatment of perianal fistulizing CD have been published
by the European Crohn’s and Colitis Organisation (ECCO) in
2016.42 Contrast-enhanced pelvic MRI should be the initial
procedure for assessment of perianal fistulizing CD which has
an accuracy of 76–100% for fistulas and might also provide
additional information, such as presence of stenosis.42,43 If a
rectal stenosis has been excluded, a good alternative to MRI
might be an endoscopic anorectal ultrasound (EUS) which has
an accuracy of 56–100%. EUS should ideally performed using
hydrogen peroxide or simple carbonated water (which is less
painful) enhancement.42,44 Endoscopy plays also a key role in
the initial diagnosis of perianal disease. Since the extent of
inflammation in the affected parts of the intestinal tract has
prognostic and therapeutic relevance and also aids in deciding
whether medical therapy should be combined with surgical
therapy, rectosigmoidoscopy should routinely be performed
during initial assessment of perianal fistulizing CD.42,45
According to current literature, EUA is the most sensitive
diagnostic procedure with an accuracy of 90%. On the one
hand, it can enhance the sensitivity and specificity of MRI and
EUS. On the other hand, EUA provides also the advantage for
performing concomitant surgical procedures. When an
abscess is suspected, EUA should immediately be performed
and abscess drainage conducted even before MRI examina-
tion. According to the ECCO guidelines from 2016, once a
perianal fistula is detected, EUA is considered to be the
gold standard when performed by an experienced
surgeon.2,42,43,46,47 Fistulography is no longer recommended
by the ECCO,42 due to clear-cut superiority of MRI in depicting
fistula tract anatomy in higher resolution including the tract-
surrounding space, for example, abscess formation and
extension thereof or muscular penetration and destruction.
Treatment. In terms of limited ongoing basic research
initiatives, it becomes evident that available treatment options
and high-class evidence clinical trials are in a striking
discrepancy to the relatively high burden of fistula in CD
patients. Fortunately, this deficit has received more attention
within the last few years. However, it remains to be stressed,
that dedicated clinical trials with healing of fistula or reduction
in the amount of secreting fistula tracts are still limited.
Therefore, most of the evidence on the following treatment
options is derived from subgroup analyses or ill-defined
secondary outcome measures. As a consequence, any
interpretation of the effectiveness of agents (above all
comparative statements) have to be made with great caution.
The latter is underlined by a recent meta-analysis of placebo
response rates in fistulizing CD, revealing that almost one in
six patients receiving placebo reported fistula closure.48
Indeed, there are hardly any topics in the field of IBD, where
the almost omnipresent statement—“further studies are
needed to better…”—is that much justified as in fistulizing
CD. In the following a brief overview of available treatment
options will be provided. Any interventions with course of
fistulizing CD investigated as primary objective/endpoint are
highlighted with a plus symbol (+).
Antibiotics. The role of antibiotics in fistulizing CD rather
founds on decades of clinical experience than robust
Figure 1 Pathogenesis of Crohn’s disease-associated fistulae. Due to an epithelial barrier defect several pathogen-associated molecular patterns (PAMPs), like e.g.,
muramyl-dipeptide (MDP), as well as bacteria are able to enter the gut mucosa. The resulting inflammatory response induces the event of epithelial-to-mesenchymal transition
(EMT). First, an increased expression of tumor necrosis factor (TNF) is initiated, resulting in an upregulation of TGF-β production. This triggers a signaling cascade of molecules
associated with matrix remodeling, in particular enhanced activity of matrix metalloproteinases (MMPs) and cell invasiveness, such as β6-Integrin. These events favor the
transformation of the intestinal epithelial cells (IECs) towards invasive myofibroblast like cells, what finally results in fistula formation.
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scientific evidence49,50 (+51,52). As antibiotics do not induce
fistula healing in the vast majority of cases, their primary role
is to address penetrating complications, improve symptoms
including drainage on the short- to midterm and act as an
adjunctive treatment in surgical management, such as for
instance seton placement. Antibiotics should not be con-
sidered and used as a sole therapeutic concept in itself in
fistulizing disease,45 but as an adjunct in combination with
surgical management or medical treatment, especially anti-
TNF53,54) and to a lesser extent with azathioprine.55
Aminosalicylates. To date, there is no evidence for the
efficacy of 5-ASA agents for the treatment of fistulizing CD,
neither for orally nor rectally applied formulations. Therefore,
these agents cannot be recommended for this indication.
However, there might be a role especially for rectal applied
5-ASA formulations to address clinical symptoms of active
rectal inflammation, such as fecal urgency or lower abdom-
inal pain and potentially also to act synergistically with other
topical or systemic agents to reduce inflammatory activity in
the rectum. Although such a potential synergistic effect has
never been systematically studied, addressing inflammation
in the rectum as profound as possible by means of medical
treatment remains an important prerequisite for subsequent
successful surgical treatment.
Corticosteroids. There is no data to support the use of
corticosteroids in fistulizing CD. In fact, older therapeutic
observations have reported on a worsening of clinical
symptoms upon treatment with steroids,56 which is why both
topical and systemic corticosteroids, do not have any place in
this indication.
Thiopurines and methotrexate. The evidence for thiopurines
is considerably limited, including a subgroup analysis from a
randomized trial of some 80 patients with CD from the 1980s
with an impressive complete fistula healing rate of 31%57 as
well as metaanalyses with conflicting results on presence58
or absence59 of overall effectiveness. In a small study, a
“sonic-like” increase in fistula closure rates in combined
thiopurine/infliximab treatment was suggested (+60). With the
exception of a small case series with some thirty CD patients
suggesting a benefit with partial or complete fistula closure in
more than 50% of patients,61 there are no studies on the
potential role of Methotrexate in this indication.
Calcineurin inhibitors. There are only observational studies
with cyclosporine in fistulizing CD. The bottom line of these
investigations may be subsumed as a robust effectiveness
in the short-term with however a high rate of relapse after
withdrawal of cyclosporine.62–64 In contrast, a trial with
tacrolimus dedicated to investigate fistula healing revealed
a significant effect in the amount of patients achieving of at
least 50% of their fistulas to be closed (+65). In contrast,
although a beneficial effect regarding inflammatory activity in
the rectum was observed by the topical administration of
tacrolimus, there was no effect on fistula closure.66
Anti-TNF. By far, the data with anti-TNF in fistulizing CD are
the most robust in terms of both, efficacy and scientific
quality. Infliximab (IFX) revealed to achieve impressively high
complete (55 vs. 13% placebo) and partial (i.e., reduction of
50% or more of draining fistula; 68 vs. 26% placebo) fistula
closure rates (+67). Patients with maintenance IFX treatment
were found to show significantly higher rates of durable
response68). It remains unclear however, why the efficacy
rates in this trial in the higher induction dose arm (10 m/kg)
revealed to be somewhat lower. In any case, a recent
multicenter trial (currently only published in abstract form,
DDW 2016, +69) with 117 patients revealed an incremental
gain in efficacy rates with higher doses and IFX trough levels
with fistula healing rates (defined as absence of draining
fistula) in up to 80% in the patients with very high trough
levels (IFX≥20, 2 μg/ml). In a small prospective study
including 32 patients the combination of surgical manage-
ment (EUA and seton placement if indicated) revealed that
antecedent surgical intervention increases initial and long-
term response rates (+70). Achieving initial response (radi-
ological healing as assessed by MRI) was found to be a
strong predictor of long-term response and concomitant
treatment with thiopurines appeared to be beneficial
(+71,72). In the long-term, about two out of three patients
appeared to achieve persistent fistula closure, whereas one
out of three patients suffered from recurrence in a retro-
spective analysis of 156 CD patients with perianal disease
receiving IFX.72 Regarding adalimumab, there are no trials
investigating fistula closure as primary endpoint. In the major
trials evaluating efficacy of adalimumab for induction of
remission in previously anti-TNF naïve (CLASSIC-I73 and
exposed patients (GAIN74), no difference in fistula closure
rates to placebo were observed. In contrast, a higher rate of
complete fistula healing (33 vs. 13% in the placebo group)
was observed in a subgroup analysis of the maintenance trial
(CHARM75), including an open label extension phase,
revealing high rates of sustained fistula healing in
responders.76 The major Certolizumab pegol trials in CD
(PRECiSE 177 and 278)—both not designed to investigate this
issue, however—did not reveal superiority of the verum
compared with placebo. A subgroup analysis of patients with
a response on active fistulizing CD indicated a benefit in
those patients with ongoing drug treatment.79
Anti-integrin. Up to present, there is no specific clinical trial
investigating a potential effect of vedolizumab on fistula
closure in CD. However, a study with fistula healing at week
30 as primary endpoint appears to be currently recruiting
patients (NCT02630966). In the GEMINI 2 study,80 fistula
closure was a pre-specified endpoint. The maintenance
population with continuous vedolizumab exposure achieved
fistula closure at week 52 in a higher percentage (30.8%) as
compared to those patients being re-randomized to placebo
(11.1%).81 However, patient numbers were extremely small
(higher fraction of responders 7 out of 18, 41.2% in the 8 week
vs. the 4 week treatment interval group, 5 out of 22 patients,
22.7%), and therefore, results of the above-mentioned study
have to be awaited until any verdict on the potential
effectiveness of this agent in fistulizing CD can be reached.
Emerging local cell-based treatment options. First small
studies about 7 years ago using topically administered
mesenchymal stem cells in fistulizing CD revealed promising
results (+82,83). A recent study in the Netherlands with 21
refractory fistulizing CD patients investigated the effect of
locally administered bone marrow-derived mesenchymal
stromal cells in three different dosings (group 1–3) in a
placebo-controlled, double-blind trial, with fistula healing (no
discharge, no fluid collection 42 cm—assessed by physical
Crohn’s Fistula
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examination and MRI, respectively, +84). Although the results
may be considered highly promising, it remains difficult to
interpret, whether a virtual absence of efficacy in the highest
dosing group compared to the placebo group rather is
indicative of a statistical problem due to small numbers (i.e.,
coincidence) or should rather raise concern on the potential
overall efficacy of this intervention. A large randomized trial in
Europe compared the effect of a one-time intralesional
injection of 120 million allogenic, expanded, adipose-
derived stem cells (applied by an unblinded surgeon) with
placebo (1:1) in 212 patients. A blinded gastroenterologists
assessed closure of all treated external fistula openings with
baseline drainage and absence of collections 42cm, the
primary endpoint, at 24 weeks (+85). This endpoint was
achieved in a significantly higher proportion of patients (50%,
ITT) in the verum group as compared to placebo (34%). No
relevant adverse events were observed, aside from a higher
rate of local events indicative of treatment failure (e.g., anal
abscess) in the placebo group.
Varia. A variety of other treatment options have been
suggested in fistulizing CD, including oral adsorptive carbon
(AST -120, with highly promising initial results in a trial from
Japan (+86), which however could not be confirmed in a
subsequent very large trial (+87)), hyperbaric oxygen (cur-
rently only human pilot data in abstract form available, ECCO
2017, P576) or thalidomide.88 None of these options can,
however, be recommended according to at present highly
limited or conflicting data, availability of the drug or side
effects.
Surgical treatment options. A detailed overview on the
surgical treatment options of fistulizing CD is beyond the
scope of this review and we would like to refer the reader to
excellent available compilations on surgical management of
this condition.89–92 Amongst the interventions, that have been
investigated in detail are surgical drainages of perianal
abscesses in combination with IFX to prevent worsening
septic complications,93 seton placement,94,95 fistulotomy for
superficial, and low intersphincteric but not higher trans-
sphincteric fistula,14 fistula plug (success rates considerably
lower in follow-up as opposed to initial trials96,97), potentially
also as a second consecutive treatment option after seton
removal98), ligation of the intersphincteric fistula tract99 and
fibrin glue.100,101 It should be underlined that an important
prerequisite for the success of any surgical intervention is a
best possible control of inflammatory activity in the rectum by
means of medical treatment options.16
CONCLUSION
Fistulas remain one of the major unmet needs in the treatment
of CD patients. To date, only a limited number of effective
therapies has been established. Thus, the number of patients
with severe and recurrent problems arising from CD fistulas is
considerably high while surgery, though often required, does
not always provide a definitive cure. As also our understanding
of fistula pathogenesis is limited to date, further research is
warranted to on the one hand obtain a better understanding of
the complex mechanisms underlying fistula development and,
on the other hand, for identifying and establishing novel and
hopefully more effective treatment options for fistula therapy.
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